ArticleFrontiers in endocrinology2025
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Pancreatic β-cell dysfunction is a key contributor to the development of Type 2 Diabetes. The platelet-derived growth factor receptor α (PDGFRα) is known to play a crucial role in β-cell proliferation and expansion. However, its specific role in β-cell function and glucose metabolism remains unclear. This study aimed to investigate the effects of Pdgfrα deficiency on islet β-cell function and overall glucose metabolism. Methods: To explore this, we generated β-cell-specific Pdgfrα-deficient C57BL/6 mice (Pdgfra Results: Pdgfrα-deficient mice exhibited significantly greater weight gain and increased body fat compared to controls. These mice also showed impaired glucose metabolism, reduced insulin content in β-cells, and increased β-cell apoptosis. Mechanistic studies revealed that Pdgfrα deletion led to suppression of Atf5 expression via downregulation of the PI3K pathway. This suppression resulted in enhanced β-cell apoptosis. Furthermore, Atf5 was found to regulate the expression of Gadd45b, Bcl2, and aminoacyl-tRNA synthetases, which are involved in insulin biosynthesis and glucose metabolism. Discussion: Our findings demonstrate that PDGFRα plays a critical role in maintaining β-cell function and glucose homeostasis. Loss of PDGFRα impairs β-cell survival and insulin production, likely through the PI3K-Atf5 axis. These insights suggest that targeting β-cell apoptotic pathways, particularly involving Atf5 and its downstream effectors, may offer promising avenues for the prevention and treatment of Type 2 Diabetes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.